Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab
Status:
Completed
Trial end date:
2010-03-10
Target enrollment:
Participant gender:
Summary
To assess the tolerability and the initial safety profile of Inotuzumab Ozogamicin (CMC-544)
in combination with Rituximab in patients with B-Cell Non-Hodgkin's lymphoma (NHL).